Search Articles

View query in Help articles search

Search Results (1 to 10 of 13 Results)

Download search results: CSV END BibTex RIS


Education and Symptom Reporting in an mHealth App for Patients With Cancer: Mixed Methods Development and Validation Study

Education and Symptom Reporting in an mHealth App for Patients With Cancer: Mixed Methods Development and Validation Study

“CONTIGO” m Health app Interface: (A) login screen, (B) home screen, (C) patient profile, (D) the journey section, (E) quality of life questionnaire, (F) PRO-CTCAE toxicity detection questionnaire, (G) symptom reporting module, (H) educational content (text and images), (I) educational content (videos), and (J) notes section. In this study, the validation strategy reported in TGUM-GISSIC groups was applied and adapted to the current Chilean context in Chile.

Carolina Muñoz Olivar, Miguel Pineiro, Juan Sebastián Gómez Quintero, Carlos Javier Avendaño-Vásquez, Pablo Ormeño-Arriagada, Silvia Palma Rivadeneira, Carla Taramasco Toro

JMIR Hum Factors 2025;12:e60169

The Effect of Nurse Navigators in Digital Remote Monitoring in Cancer Care: Case Study Using Structural Equation Modeling

The Effect of Nurse Navigators in Digital Remote Monitoring in Cancer Care: Case Study Using Structural Equation Modeling

This study aims to fill this gap by examining the impact of NNs in the Cancérologie parcours région Ile-de-France (CAPRI) DRM program, considering factors such as toxicity management and care use. CAPRI is an application of DRM in oncology. It specifically targets patients receiving oral anticancer agents, focusing on improving adherence, managing toxicities, and enhancing overall patient care.

Etienne Minvielle, Joel Perez-Torrents, Israa Salma, Philippe Aegerter, Marie Ferrua, Charles Ferté, Henri Leleu, Delphine Mathivon, Claude Sicotte, Mario Di Palma, Florian Scotté

J Med Internet Res 2025;27:e66275

e-Cigarette Tobacco Flavors, Public Health, and Toxicity: Narrative Review

e-Cigarette Tobacco Flavors, Public Health, and Toxicity: Narrative Review

Therefore, by analyzing the toxicity, characteristics, sales, social media perception, and public health aspects of tobacco-flavored e-cigarettes, this review aims to inform authorities about this issue and provide information for potential interventions (Figure 1). A schematic of the discussion of new tobacco-flavored e-cigarettes and their associated problems. FDA: Food and Drug Administration.

Yehao Sun, Prital Prabhu, Ryan Rahman, Dongmei Li, Scott McIntosh, Irfan Rahman

Online J Public Health Inform 2024;16:e51991

Vaping: Public Health, Social Media, and Toxicity

Vaping: Public Health, Social Media, and Toxicity

Therefore, the toxicity of nicotine salt products should be more serious than that of freebase nicotine products, but the threat of the availability of freebase nicotine along with nicotine salt is also not neglectable. Besides the toxicities specific to nicotine salts, there are various toxic effects of almost all the components in the e-liquids [15-24].

Yehao Sun, Prital Prabhu, Dongmei Li, Scott McIntosh, Irfan Rahman

Online J Public Health Inform 2024;16:e53245

Safety, Tolerability, and Dose-Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis: Protocol for a Phase 1 Clinical Trial to Determine Safety and Identify Side Effects

Safety, Tolerability, and Dose-Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis: Protocol for a Phase 1 Clinical Trial to Determine Safety and Identify Side Effects

However, patients receiving methadone will be excluded from participation in Safety, Tolerability, and Dose-Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis (STTEPP), as this is a μ-opioid agonist and acts as an antagonist of the N-methyl-D-aspartate (NMDA) receptor [26]. Several studies have evaluated lacosamide as a monotherapy for clinical pain conditions such as fibromyalgia and painful diabetic peripheral neuropathy.

Evan L Fogel, Jeffrey J Easler, Ying Yuan, Dhiraj Yadav, Darwin L Conwell, Santhi Swaroop Vege, Samuel Y Han, Walter Park, Vanessa Patrick, Fletcher A White

JMIR Res Protoc 2024;13:e50513

Impact of a Mobile App (LoAD Calc) on the Calculation of Maximum Safe Doses of Local Anesthetics: Protocol for a Randomized Controlled Trial

Impact of a Mobile App (LoAD Calc) on the Calculation of Maximum Safe Doses of Local Anesthetics: Protocol for a Randomized Controlled Trial

While the advantages of such techniques are undeniable, using high LA doses increases the risk of local anesthetic systemic toxicity (LAST), a potentially lethal complication associated with the use of these agents [2]. The actual incidence of LAST is unknown since most minor symptoms are not specific and because LAST awareness varies considerably between practitioners [3,4].

Pietro Elias Fubini, Georges Louis Savoldelli, Tal Sara Beckmann, Caroline Flora Samer, Mélanie Suppan

JMIR Res Protoc 2024;13:e53679

FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases (FAST-01): Protocol for the First Prospective Feasibility Study

FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases (FAST-01): Protocol for the First Prospective Feasibility Study

FLASH is an emerging radiation treatment modality that has shown promise for improving the therapeutic ratio by potentially reducing normal tissue toxicity when compared to conventional radiotherapy. FLASH treatment is delivered at ultrahigh dose rates of at least 40 Gy per second, which is approximately 1000 times the dose rate of conventional radiotherapy.

Emily C Daugherty, Anthony Mascia, Yong Zhang, Eunsin Lee, Zhiyan Xiao, Mathieu Sertorio, Jennifer Woo, Claire McCann, Kenneth Russell, Lisa Levine, Ricky Sharma, Deepak Khuntia, Jeffrey Bradley, Charles B Simone II, John Perentesis, John Breneman

JMIR Res Protoc 2023;12:e41812

Developing a Mobile Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Administration System to Capture Postradiation Toxicity in Oncology: Usability and Feasibility Study

Developing a Mobile Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Administration System to Capture Postradiation Toxicity in Oncology: Usability and Feasibility Study

Toxicity reporting via the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) is mandatory in oncology clinical trials to monitor patient safety and to understand the toxicity profiles of treatments [1]. Several studies have shown that symptomatic toxicities associated with anticancer treatments (eg, nausea and vomiting) are frequently underreported by health care providers, even when prospectively collected within clinical trials [2-5].

Jody Underwood, Susan McCloskey, Ann Raldow, Amar Kishan, Chad Zalkin, Daniel Navarro, Lisa Scott Holt, Andrew Webb, Kathleen A Lynch, Thomas M Atkinson

JMIR Form Res 2022;6(4):e27775